Literature DB >> 1590686

Double-blind randomized study of the effect of infusion rates on toxicity of amphotericin B.

M E Ellis1, A A al-Hokail, H M Clink, M A Padmos, P Ernst, D G Spence, W N Tharpe, V F Hillier.   

Abstract

Results of a double-blind randomized non-crossover study of rapid (45 min) versus slow (4 h) infusion of amphotericin B administered to 20 patients with proven or suspected fungal infection are reported. Toxicity was higher in the rapid infusion group than it was in the slow infusion group (mean total 7-day chill score, 173 +/- 276 versus 20 +/- 30 [P less than 0.01]; mean total 7-day dosage of meperidine required to abate rigors, 180 +/- 133 versus 58 +/- 78 mg [P less than 0.05]; and mean maximum total 7-day pulse rise, 225 +/- 64 versus 135 +/- 56 beats per min [P less than 0.02], respectively). When analyzed on a daily basis, the mean chill score, meperidine dosage, and pulse rise were also higher; and in addition, nausea and vomiting (5 of 11 patients who received a rapid infusion versus 0 of 9 patients who received a slow infusion [P less than 0.01]) appeared to be more common in those who received amphotericin B rapidly. The daily analysis approach proved that tolerance to these side effects developed with each subsequent infusion day, and by day 7 the incidence and severity were the same. This development of tolerance was significant for the mean chill score in the rapid infusion group (P less than 0.05) and for the proportion of patients with chills (P less than 0.005 for the slow infusion group; P less than 0.05 for the rapid infusion group). A decrease in creatinine clearance to greater than 51% of the baseline value was seen in two patients in each group. There were five deaths (four in the rapid infusion group, 1 in the slow infusion group) within 1 month, but none was clearly related to the amphotericin B infusion. The mean time to defervescence was similar for each group (10.8 +/- 4.1 days in the slow infusion group versus 9.9 +/- 5 days in the rapid infusion group). A rapid infusion regimen for amphotericin B cannot be recommended, at least during the first 5 to 7 days of treatment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1590686      PMCID: PMC189248          DOI: 10.1128/AAC.36.1.172

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Randomized, double-blind trial of 1- versus 4-hour amphotericin B infusion durations.

Authors:  E C Oldfield; P D Garst; C Hostettler; M White; D Samuelson
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

2.  Effect of infusion rate on amphotericin B-associated febrile reactions.

Authors:  J D Cleary; D Weisdorf; C V Fletcher
Journal:  Drug Intell Clin Pharm       Date:  1988-10

3.  CKryptococcosis treated by rapid infusion of amphotericin B.

Authors:  R A Tarala; J D Smith
Journal:  Br Med J       Date:  1980-07-05

4.  Stability of amphotericin B in 5% dextrose injection at concentrations used for administration through a central venous line.

Authors:  P E Kintzel; P E Kennedy
Journal:  Am J Hosp Pharm       Date:  1991-02

5.  Risk factors of ventricular fibrillation during rapid amphotericin B infusion.

Authors:  P C Craven; D H Gremillion
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

6.  Rapid infusion amphotericin B: effective and well-tolerated therapy for neutropenic fever.

Authors:  T R Spitzer; R J Creger; R M Fox; H M Lazarus
Journal:  Pharmatherapeutica       Date:  1989

Review 7.  Drug prescribing in renal failure: dosing guidelines for adults.

Authors:  W M Bennett; G R Aronoff; G Morrison; T A Golper; J Pulliam; M Wolfson; I Singer
Journal:  Am J Kidney Dis       Date:  1983-11       Impact factor: 8.860

  7 in total
  8 in total

1.  Effect of infusion rates on toxicity of amphotericin B.

Authors:  H D Davies; A Matlow; S King; G Koren
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

2.  Controlled pilot study of rapid amphotericin B infusions.

Authors:  H Dele Davies; S M King; J Doyle; A Matlow; G Koren; R Hamilton; C Portwine
Journal:  Arch Dis Child       Date:  1997-02       Impact factor: 3.791

3.  Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial.

Authors:  U Eriksson; B Seifert; A Schaffner
Journal:  BMJ       Date:  2001-03-10

Review 4.  Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia.

Authors:  Helle Krogh Johansen; Peter C Gøtzsche
Journal:  Cochrane Database Syst Rev       Date:  2014-09-04

Review 5.  Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients.

Authors:  Helle Krogh Johansen; Peter C Gøtzsche
Journal:  Cochrane Database Syst Rev       Date:  2014-09-04

6.  Accumulation of amphotericin B in human macrophages enhances activity against Aspergillus fumigatus conidia: quantification of conidial kill at the single-cell level.

Authors:  B Jahn; A Rampp; C Dick; A Jahn; M Palmer; S Bhakdi
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

7.  continuous versus conventional infusion of amphotericin B deoxycholate: a meta-analysis.

Authors:  Matthew E Falagas; Drosos E Karageorgopoulos; Giannoula S Tansarli
Journal:  PLoS One       Date:  2013-10-21       Impact factor: 3.240

Review 8.  Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B.

Authors:  Jill Adler-Moore; Russell E Lewis; Roger J M Brüggemann; Bart J A Rijnders; Andreas H Groll; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2019-05-02       Impact factor: 9.079

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.